ARQT
Arcutis Biotherapeutics, Inc.
September 16, 2026 · intraday
- Rarity
- 1.94
- Peak move
- +11.43%
- Float cap
- $2.6B
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological diseases. It markets ZORYVE cream and foam, once-daily steroid-free PDE4 inhibitors, for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in adults and pediatric patients. It sells primarily to dermatology and primary care prescribers and patients in the United States and Canada, with licensing partners in Greater China, Southeast Asia, and Japan.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 2 from SEC or newswire · 0 timed with the moveanalyst_ratingWeiss Ratings cut Arcutis Biotherapeutics to a 'hold (c-)' rating from 'hold (c)' in a report dated Tuesday, September 8, 2026.
- Key event
insider_saleFormer officer Larry Todd Edwards filed notice to sell 341,980 common shares of Arcutis Biotherapeutics at an average price of $25.00, a market value of about $8.5 million.
SEC144 0001628280-26-062242 - Key event
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference on Sept 16, 2026, Arcutis CEO Frank Watanabe and other management discussed ~$240 million in cash, an intent to remain quarterly cash-flow positive absent a major business development deal, ZORYVE growth, an infant atopic dermatitis PDUFA date of February 2027, a Q4 2026 vitiligo Phase 2 readout, and the ARQ-234 pipeline.
- Key event
insider_saleArcutis Biotherapeutics director Howard Welgus filed a Form 144 notice to sell 4,730 common shares at an average price of $24.18, a market value of about $114,371, under a Rule 10b5-1 plan through Merrill Lynch, after selling 10,095 shares for $267,419 in the prior three months.
SEC144 0001628280-26-062042Webarchive.fast-edgar.com index_rebalanceS&P Dow Jones Indices will add Arcutis Biotherapeutics to the S&P SmallCap 600 index as part of its quarterly rebalance, effective before the open on Sept 21, 2026.
analyst_ratingSeeking Alpha published a report downgrading Arcutis Biotherapeutics to Hold from Buy, citing competition, single-asset dependency on Zoryve, topical market softness and generic threats.